These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J. J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [Abstract] [Full Text] [Related]
6. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center. Wu HT, Peng KW, Ji ZH, Sun JH, Zhang Q, Yang XJ, Huang CQ, Li Y. Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924 [Abstract] [Full Text] [Related]
15. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J. Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [Abstract] [Full Text] [Related]
16. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [Abstract] [Full Text] [Related]
17. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. Marcotte E, Dubé P, Drolet P, Mitchell A, Frenette S, Leblanc G, Leclerc YE, Sideris L. World J Surg Oncol; 2014 Nov 07; 12():332. PubMed ID: 25380618 [Abstract] [Full Text] [Related]
20. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, Nienhuijs SW, de Hingh IH. Ann Surg Oncol; 2015 Apr 07; 22(4):1236-42. PubMed ID: 25319584 [Abstract] [Full Text] [Related] Page: [Next] [New Search]